A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer
- Conditions
- LymphomaNon-Hodgkin's LymphomaHodgkin DiseaseMultiple MyelomaLeukemiaLymphocytic
- Interventions
- Registration Number
- NCT01149668
- Lead Sponsor
- Pharmacyclics LLC.
- Brief Summary
The purpose of this study is to determine the long-term (\> 6 months) safety of PCI 24781 PO in subjects with lymphoma.
- Detailed Description
An open-label, monotherapy, multicenter, extension study open to subjects who have derived benefit from PCI 24781 PO for at least 6 months and want to continue receiving study drug.
Subjects enrolled in this study will receive PCI-24781 at the schedule and dosage from their prior protocol. Treatment may be continued as long as there is no evidence of progressive disease or unacceptable toxicity.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 7
- Men and women with cancer that did not progress while treated with PCI 24781 PO for at least 6 months and who want to continue receiving study drug
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
- Agreement to use contraception during the study and for 30 days after the last dose of study drug if sexually active and able to bear children
- Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty
- Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local subject privacy regulations)
- A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of oral PCI-24781, or put the study outcomes at undue risk
- Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification
- Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
- Immunotherapy, chemotherapy, radiotherapy, corticosteroids (at dosages equivalent to prednisone > 20 mg/day) or experimental therapy (other than PCI-24781 PO) within 4 weeks before first dose of study drug
- Concomitant use of medicines known to cause QT prolongation or torsades de points (see Appendix 2)
- Central nervous system involvement by lymphoma
- Known history of Human Immunodeficiency Virus (HIV) or active infection with Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV) or any uncontrolled active systemic infection
- Creatinine > 1.5 x institutional upper limit of normal (ULN); total bilirubin > 1.5 x ULN (unless due to Gilbert's disease); and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 x ULN
- Lactating or pregnant
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description PCI-24781 PCI-24781 -
- Primary Outcome Measures
Name Time Method Safety 30 days after last dose of study drug frequency, severity and relatedness of adverse events
- Secondary Outcome Measures
Name Time Method Tumor Response frequency of tumor assessments done per standard of care tumor response will be assessed per established response criteria. This study will capture time to disease progression and duration of response.
Trial Locations
- Locations (5)
Northwestern Univ. Med School
🇺🇸Chicago, Illinois, United States
Nebraska Methodist Hospital
🇺🇸Omaha, Nebraska, United States
Univ. of Nebraska Medical Center
🇺🇸Omaha, Nebraska, United States
Horizon Oncology Center
🇺🇸Lafayette, Indiana, United States
Sarah Cannon Research Institute
🇺🇸Nashville, Tennessee, United States